$AZN News

AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update

Onco360® Has Been Selected as a National Pharmacy Partner for ZEGFROVY® (sunvozertinib)

AstraZeneca (LSE:AZN) Posted Positive Phase III Results For Three Cancer Drugs

Is AstraZeneca’s Pipeline Fuel Enough to Spark a Post-Earnings Breakout on Oct. 30?

AstraZeneca: Stomach Cancer Drug With $3 to $5 Billion Sales Potential, and One Significant Wrinkle

Astrazeneca Reports Higher Patient Survival Rates in Stomach, Lung-Cancer Drug Trials

AstraZeneca Announced Saturday,Perioperative IMFINZI Plus Neoadjuvant Enfortumab Vedotin Cuts Recurrence Risk 49%, Death Risk 42% Versus Standard Of Care In Muscle-Invasive Bladder Cancer Patients Ineligible For Or Refusing Cisplatin, VOLGA Phase III

AstraZeneca Announced Saturday, IMFINZI Plus Tarlatamab-dlle Cuts Death Risk 58% Versus IMFINZI Alone In First-Line Extensive-Stage Small Cell Lung Cancer, Median OS 21.1 Versus 12.7 Months, In DeLLphi-305 Phase III

Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01

TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy

AstraZeneca Launches Targeted Lung Cancer Drug In US After FDA Accelerated Approval

Summit Expands Ivonescimab Development Into Biliary Tract Cancer

AstraZeneca bags another US indication for Ultomiris with IgAN approval

FDA Conditionally Approves AstraZeneca's Rare Kidney Disease Drug

ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations

AstraZeneca Launches ZEGFROVY In The U.S., Expanding Targeted Treatment Options For EGFR Exon 20 Insertion-Mutated Lung Cancer

AstraZeneca (LSE:AZN) Reports Positive Phase III Results In Eosinophilic Esophagitis